We are live on ! Find out more
TXG icon

10x Genomics

289 hedge funds and large institutions have $3.87B invested in 10x Genomics in 2024 Q1 according to their latest regulatory filings, with 57 funds opening new positions, 112 increasing their positions, 76 reducing their positions, and 42 closing their positions.

New
Increased
Maintained
Reduced
Closed

266% more call options, than puts

Call options by funds: $14.3M | Put options by funds: $3.9M

52% more capital inflows, than outflows

Capital inflows: $764M | Capital outflows: $503M

47% more repeat investments, than reductions

Existing positions increased: 112 | Existing positions reduced: 76

36% more first-time investments, than exits

New positions opened: 57 | Existing positions closed: 42

5.95% more ownership

Funds ownership: 92.14% → 98.09% (+6%)

5% more funds holding

Funds holding: 275 → 289 (+14)

25% less funds holding in top 10

Funds holding in top 10: 8 → 6 (-2)

Holders
289
Holders Change
+14
Holders Change %
+5.09%
% of All Funds
4.15%
Holding in Top 10
6
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-25%
% of All Funds
0.09%
New
57
Increased
112
Reduced
76
Closed
42
Calls
$14.3​M
Puts
$3.9​M
Net Calls
+$10.4​M
Net Calls Change
-⁠$5.3​M

TXG Hedge Fund Activity: Q1 2024 in Review

289 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q1 2024, worth a combined $3.87B — down 28% from $5.37B a quarter earlier.

Buyers outnumbered sellers: 57 funds opened new TXG positions and 42 closed out — a net gain of 15 holders — while 112 added to existing stakes and 76 trimmed.

The largest buyer was ARK Investment Management, adding an estimated $98.5M. The largest seller was Invesco, cutting an estimated $98.9M.

  • 289 institutional investors held 10x Genomics (TXG) as of Q1 2024, up from 275 in Q4 2023.
  • Funds reported $3.87B of 10x Genomics stock for Q1 2024, down 28% quarter-over-quarter.
  • 57 funds opened new 10x Genomics positions in Q1 2024 and 42 closed out, a net change of +15 holders.
  • The largest 10x Genomics buyer in Q1 2024 was ARK Investment Management, an estimated $98.5M added.
  • The largest 10x Genomics seller in Q1 2024 was Invesco, an estimated $98.9M sold.

Based on aggregated 13F filings for Q1 2024.